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Weekly administration of nanoparticle albumin-bound paclitaxel (nab-paclitaxel)
has been shown to be a safe and effective treatment for metastatic breast cancer
(MBC) in clinical studies. We conducted a multicenter, randomized, open-label
phase II study to compare the efficacy and safety of weekly nab-paclitaxel and
docetaxel in Japanese patients with human epidermal growth factor receptor
2-negative MBC. The primary endpoint was progression-free survival (PFS).
Patients were randomized to receive nab-paclitaxel (150 mg/m2 nab-paclitaxel
once per week for 3 of 4 weeks; n = 100) or docetaxel (75 mg/m2 docetaxel every
3 weeks; n = 100). The median PFS by independent radiologist assessment was
9.8 months (90% confidence interval [CI]: 8.5–11.2) for nab-paclitaxel and
11.2 months (90% CI: 8.4–13.8) for docetaxel (hazard ratio: 1.25, P = 0.363), and
the median overall survival was 42.4 months and 34.0 months, respectively. The
overall response rate was 56.1% for nab-paclitaxel and 52.5% for docetaxel.
Adverse events in both treatment arms were similar to previous reports. Neu-
tropenia was the most common adverse event in both arms, with 35.0% of
patients in the nab-paclitaxel arm and 89.0% in the docetaxel arm experiencing
grade 4 neutropenia. Grade 3 peripheral sensory neuropathy occurred in 22.0% of
patients in the nab-paclitaxel and 5.0% in the docetaxel arm. In this study,
although weekly nab-paclitaxel 150 mg/m2 did not show superiority in PFS com-
pared with docetaxel, efficacy outcomes were similar in patients treated with
weekly nab-paclitaxel and docetaxel.
B reast cancer is the most common cancer among Ameri-can and Japanese women,(1) with about one in eight
(12%) women in the United States and one in 16 (6%) in
Japan developing invasive breast cancer during their lifetime.
In Japan, the predicted incidence of breast cancer is 90 000
(the most common cancer in women), with 14 000 breast
cancer deaths (the fifth leading cause of death in women) in
2016.(2)
Taxane-containing regimens were shown to improve overall
survival (OS) in women with metastatic breast cancer (MBC)
in a large systematic review,(3) while concurrent combined use
of anthracyclines and taxanes failed to prolong OS compared
with single and sequential use of each drug.(4–6) The single use
of taxanes, such as paclitaxel and docetaxel, has thus become
one of the first-line regimens for MBC.(7,8)
Weekly (qw) administration of paclitaxel in patients with
MBC was more effective than administration every 3-weeks
(q3w) in terms of overall response rate (ORR), time to pro-
gression and OS (CALGB 9840).(9) In an adjuvant setting,
paclitaxel qw (hazard ratio [HR]: 1.27, P = 0.006) and doc-
etaxel q3w (HR: 1.23, P = 0.02) were superior to paclitaxel
q3w in terms of disease-free survival, and OS was higher with
paclitaxel qw (HR: 1.32, P = 0.01) compared with paclitaxel
q3w.(10) Based on this evidence, patients with MBC patients
are often treated with paclitaxel qw or docetaxel q3w in clini-
cal practice.
However, solvent-based paclitaxel (sb-paclitaxel) and doc-
etaxel formulations have several limitations; both require sol-
vents (Cremophor EL or polysorbate 80) to increase their
solubility, and these solvents are associated with the
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development of hypersensitivity and decreased efficiency of
drug delivery to the tumor.(11–13) In contrast, nanoparticle albu-
min-bound paclitaxel (nab-paclitaxel) is a solvent-free albu-
min-bound form of paclitaxel, which enables it to be
administered more quickly, without the need for steroids and
anti-histamine premedication to reduce solvent-related hyper-
sensitivity reactions. Compared with sb-paclitaxel, nab-pacli-
taxel demonstrated enhanced transport across endothelial cell
monolayers and increased tumor delivery of paclitaxel.(14,15)
In a phase III trial, nab-paclitaxel q3w at a dose of 260 mg/
m2 demonstrated a significantly higher ORR compared with
sb-paclitaxel in patients with MBC.(16) Based on the results for
sb-paclitaxel, nab-paclitaxel qw is also expected to have
greater efficacy than nab-paclitaxel q3w. Additionally, nab-
paclitaxel qw has been reported to allow a facilitate relative
dose intensity, with improved antitumor activity compared
with q3w.(17,18) Indeed, a phase II study demonstrated signifi-
cantly longer progression-free survival (PFS) with nab-pacli-
taxel 150 mg/m2 qw as first-line therapy compared with
docetaxel 100 mg/m2 q3w, with a favorable safety profile in
patients with MBC, most of whom were Caucasian.(19) Nab-
paclitaxel (150 mg/m2) also showed favorable tolerability in a
phase I study involving Japanese patients with MBC.(20)
Based on these results, we investigated further qw dosing
schedules of nab-paclitaxel in Japanese patients with MBC.
Docetaxel 75 mg/m2 was determined to be a tolerable dose
based on previous studies in Japanese breast cancer
patients.(21) We therefore aimed to compare the efficacy and
safety profiles of nab-paclitaxel 150 mg/m2 qw and docetaxel
75 mg/m2 in Japanese patients with MBC.
Materials and Methods
Study design. This multicenter, randomized, controlled,
open-label phase II study was conducted at 21 sites in Japan.
The primary endpoint was PFS by independent radiologist
assessment, which was defined as the time from enrollment
until tumor progression or death from any cause, with censor-
ing of patients who were lost to follow-up. The secondary end-
points were ORR (proportion of patients who achieved a
complete response [CR] or partial response [PR]), time to
treatment failure (TTF; time from the date of enrollment to
earliest date of last study drug administration, objective pro-
gressive disease [PD] or death) and OS. The disease control
rate (proportion of patients who achieved CR, PR or stable dis-
ease) was also assessed. The study was conducted in accor-
dance with the principles of the Declaration of Helsinki and
Good Clinical Practice guidelines, and was approved by the
ethical committee or review board of each institution. All
patients provided written consent before their enrollment.
Patients. The main inclusion criteria were as follows: female
sex; histologically or cytologically confirmed breast cancer;
clinically confirmed MBC, with no history of chemotherapy
after confirmation of metastasis; MBC without human epider-
mal growth factor receptor 2 overexpression determined by
immunohistochemical staining or FISH (patients with immuno-
histochemical 3+ or 2+ and FISH-positive results were
excluded from the study); at least one measurable lesion
defined by the Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.0 within 28 days prior to enrollment;
Eastern Cooperative Oncology Group performance status (PS)
of 0–1; retained organ functions; and no prior chemotherapy
except for adjuvant/neoadjuvant chemotherapy. The main
exclusion criteria were as follows: recurrence within
12 months after the last treatment with taxane therapy before/
after surgery, or progression during taxane therapy prior to sur-
gery; symptomatic or treatment-requiring brain metastasis;
pleural fluid; ascites; grade ≥2 pre-existing peripheral neuropa-
thy; or pericardial fluid requiring drainage.
Treatment. Patients were randomly assigned (1:1) via a cen-
tralized randomization system to receive either nab-paclitaxel
or docetaxel using a minimization allocation method. The ran-
domization procedure was generated by EPS Corporation
(Tokyo, Japan), independent of the sponsor. The randomization
was stratified by prior received taxanes as adjuvant therapy
(yes or no) and Eastern Cooperative Oncology Group PS (0 or
1). Nab-paclitaxel at an initial dose of 150 mg/m2 was admin-
istered intravenously over 30 min, qw for 3 of 4 weeks. Dose
reductions were permitted to manage toxicities such as neu-
tropenia, thrombocytopenia, or non-hematologic toxicities
(Table S1). Patients requiring further dose reduction than
80 mg/m2 (level 3) were withdrawn from the study (Tables
S1, S2). Dose-interruption criteria on Days 8 and 15 are shown
in Table S3. A new treatment cycle was postponed for a maxi-
mum of 21 days if one or more criteria for starting the next
cycle were not met (Table S4). The postponed cycle or omitted
dosing was resumed after confirming that the criteria to start
the next cycle were met.
Docetaxel at a dose of 75 mg/m2 was injected intravenously
over 1 h, q3w. Dose reductions to 60 and 50 mg/m2 were per-
mitted, according to the same criteria described for nab-pacli-
taxel above. Discontinuation, dose omission, and cycle
resumption were determined according to the same criteria as
for nab-paclitaxel.
The cycles for both study drugs were repeated until disease
progression, development of unacceptable toxicity, or with-
drawal of consent.
Assessments. Tumor assessment was done at screening and
every 6 weeks from randomization. Additional assessments
were carried out if disease progression was suspected. Tumor
responses were evaluated according to the RECIST version
1.0.(22) Tumor assessments were carried out by the independent
radiologist assessment (ICON Medical Imaging, PA, USA) and
by the investigators.
Adverse events were recorded and graded according to the
Common Terminology Criteria for Adverse Events version 3.0.
Statistical analysis. Efficacy data were analyzed for the full
analysis set, defined as eligible patients who received the study
drug at least once. Pre-specified subgroup analyses of OS and
PFS were performed to assess the effects of prior use of adju-
vant taxanes and of triple-negative breast cancer (TNBC). The
primary endpoint was analyzed at a 5% significance level
using the log-rank test and Cox’s proportional hazards model.
Survival was analyzed using medians with 90% or 95% confi-
dence intervals (CI), respectively, using Kaplan–Meier esti-
mates. ORR was compared between the two treatment arms
using Fisher’s exact test. TTF and OS were analyzed as for
PFS with 95% CI.
We assumed the median PFS for nab-paclitaxel 150 mg/m2
qw was 11.8 months and that for docetaxel 75 mg/m2 was
7.5 months, based on the results of a previous phase II study
by Gradishar et al.(19) We calculated that 152 patients would
be needed to demonstrate the superiority of nab-paclitaxel
150 mg/m2 qw compared with docetaxel 75 mg/m2 q3w at a
one-sided 0.05 significance level and power of 80%. Assuming
that 5% of patients might be excluded from the full analysis
set, we estimated that we required to enroll 160 patients in the
present study. During the recruitment process, we revised this
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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estimate to 192 patients to account for the fact that the number
of PD events judged by an independent radiologist assessment
tends to be lower than that judged by the investigator, based
on a previous study of 762 patients, of whom 635 were judged
to have PD according to the investigators’ assessment, com-
pared with only 521 according to the independent radiologist
assessment.(23) The number of needed events (121 events) was
not modified.
Results
Patients. From November 2009 to December 2012, 200
patients were enrolled in this study, of whom 197 were
assessed as eligible. Figure 1 shows the CONSORT flow dia-
gram of the study. A total of 200 patients were allocated to
the two treatment arms, with 100 patients in each. All 200
patients received at least one treatment and served as the
safety analysis population. Three patients were excluded from
the full analysis set because of protocol deviations, including
two in the nab-paclitaxel and one in the docetaxel arm. The
major reasons for treatment discontinuation were disease pro-
gression (57.1% nab-paclitaxel, 45.5% docetaxel) and adverse
events (26.5% nab-paclitaxel, 27.3% docetaxel) (Fig. 1). The
cut-off date for the primary endpoint was 31 January 2013,
and the median follow-up time was 23.0 months.
Patient characteristics (full analysis set) were balanced
between the nab-paclitaxel and docetaxel arms, respectively
(Table 1), including median age (60 vs 58 years), age
<65 years (76.5% vs 81.8%), ratio of TNBC (21.4% vs
15.2%), and prior receipt of taxanes as adjuvant chemotherapy
(27.6% vs 30.3%).
The median relative dose intensities for nab-paclitaxel and
docetaxel were 70.2% and 83.5%, respectively. The rates of
second-line therapy use were similar in both arms (94.9% nab-
paclitaxel vs 90.9% docetaxel).
Efficacy. The median PFS for nab-paclitaxel and docetaxel
by the independent radiologist assessment was 9.8 months
(90% CI: 8.5–11.2) and 11.2 months (90% CI: 8.4–13.8) (HR:
1.25, P = 0.363), respectively (Fig. 2a). The median PFS by
the investigator was 11.2 months (90% CI: 9.7–12.7) and
10.6 months (90% CI: 8.5–11.3) (HR: 0.81, P = 0.233),
respectively (Fig. 2b). In the subgroup of patients who did not
receive taxanes as adjuvant chemotherapy, the median PFS by
the independent radiologist assessment was 10.9 months for
nab-paclitaxel (90% CI: 8.5–12.5) and 9.9 months (90% CI:
7.8–12.6) for docetaxel (HR: 1.05, P = 0.824). There was no
significant difference in PFS between patients who had and
had not received taxanes as adjuvant chemotherapy (Table 2).
The median PFS in the subgroup of patients with TNBC, by
the independent radiologist was 6.8 months for nab-paclitaxel
(95% CI: 5.3–6.9) and 7.0 months for docetaxel (95% CI: 2.9–
9.6) (HR: 1.20, P = 0.624).
The results for tumor response, ORR, and disease control
rate are summarized in Table 3. There was no significant dif-
ference in ORR in the nab-paclitaxel arm assessed by either
the independent radiologists or investigators. The ORRs in
TNBC patients were 52.4% and 46.7% in the nab-paclitaxel
and docetaxel arms, respectively (P = 1.000).
The median TTF in the nab-paclitaxel and docetaxel arms
was 7.0 months (95% CI: 5.6–8.5) and 5.7 months (4.6–7.2)
(HR: 0.89, P = 0.414), respectively, as assessed by an inde-
pendent radiologist assessment; and 8.1 months (95% CI: 6.4–
9.2) and 5.7 months (95% CI: 5.2–8.1) (HR: 0.78, P = 0.117),
as assessed by the investigators. The median OS for nab-pacli-
taxel and docetaxel was 42.4 months (95% CI: 32.4–not
reached) and 34.0 months (95% CI: 27.6–40.0) (HR: 0.78,
P = 0.190), respectively (Fig. 2c), and the median OS in
TNBC patients was 27.1 months (95% CI: 18.1–not reached)
and 19.3 months (95% CI: 14.1–26.0) (HR: 0.56, P = 0.121).
Safety. All patients experienced some adverse events
throughout the course of the study. The commonly reported
adverse events (≥30% of patients) are summarized in Table 4.
The most frequent adverse events in the nab-paclitaxel arm
were neutropenia (97.0%), leukocytopenia (96.0%), alopecia
(95.0%), peripheral sensory neuropathy (88.0%), rash (61.0%)
and nail disorder (57.0%), and those in the docetaxel arm were
neutropenia (99.0%), leukocytopenia (99.0%), alopecia
(91.0%), peripheral sensory neuropathy (69.0%), taste distur-
bance (67.0%), and nail disorder (57.0%). Anemia, peripheral
sensory neuropathy, and rash occurred in at least 10% more
Fig. 1. CONSORT flow diagram.
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patients in the nab-paclitaxel arm compared with the docetaxel
arm, while edema, loss of appetite, and taste disturbance
occurred in at least 10% more patients in the docetaxel arm.
Dose reductions were required in 65.3% in the nab-pacli-
taxel arm and 56.6% in the docetaxel arm. The dose-reduction
rates due to neutropenia were 12.0% and 18.0%, and the inci-
dences of grade 4 neutropenia were 35.0% and 89.0% in the
nab-paclitaxel and docetaxel arms, respectively. About 6.0%
of nab-paclitaxel and 33.0% of docetaxel patients received
granulocyte colony-stimulating factor (G-CSF). Febrile neu-
tropenia occurred in 1.0% of the nab-paclitaxel arm and 8.0%
of the docetaxel arm.
Peripheral sensory neuropathy occurred in 88.0% and
69.0% of the nab-paclitaxel and docetaxel arms, respectively,
with the most severe (grade 3) occurring in 22.0% and 5.0%,
respectively. The dose reduction rate due to peripheral
sensory neuropathy was 33.0% for nab-paclitaxel and 7.0%
for docetaxel.
Serious adverse events occurred in 17 patients (17.0%) in
the nab-paclitaxel arm and 14 (14.0%) in the docetaxel arm.
Most of these serious adverse events were resolved or
improved by adequate treatment or study treatment interrup-
tion. Adverse events leading to discontinuation occurred in
34.0% of the nab-paclitaxel arm and 37.0% of the docetaxel
arm and included peripheral sensory neuropathy (8.0%), edema
(4.0%), facial palsy (3.0%), and macular edema (3.0%) in the
nab-paclitaxel arm, and edema (10.0%), peripheral sensory
neuropathy (7.0%), peripheral edema (6.0%), and interstitial
lung disease (4.0%) in the docetaxel arm. No treatment-related




Fig. 2. Kaplan–Meier plots of progression-free survival by the inde-
pendent radiologist assessment (a) and by investigators (b) Kaplan–
Meier plots of overall survival (c). CI, confidence interval.






n (%) n (%)
Sex
Female 98 (100.0) 99 (100.0)
Age (years)
Median 60.0 58.0
Range [min, max] [25, 74] [33, 74]
ECOG performance status
0 87 (88.8) 86 (86.9) F: 0.828
1 11 (11.2) 13 (13.1)
Triple negative
Yes 21 (21.4) 15 (15.2) F: 0.274
Estrogen receptor
Negative 23 (23.5) 16 (16.2) C: 0.198
Positive 75 (76.5) 83 (83.8)
Progesterone receptor
Negative 41 (41.8) 35 (35.4) C: 0.413
Positive 57 (58.2) 63 (63.6)
Unknown 0 (0.0) 1 (1.0)
Organ metastases‡
Lung 49 (50.0) 42 (42.4)
Bone 44 (44.9) 53 (53.5)
Lymph node 43 (43.9) 39 (39.4)
Liver 37 (37.8) 46 (46.5)
Surgical history
No 29 (29.6) 34 (34.3) F: 0.542
Yes 69 (70.4) 65 (65.7)
Prior adjuvant therapy with taxanes
Sb-paclitaxel 13 (13.3) 20 (20.2) F: 0.252
Docetaxel 14 (14.3) 10 (10.1) F: 0.392
Analysis set: full analysis set. †F, Fisher’s exact test; C, v2 test. ‡Multiple
answers allowed. ECOG, Eastern Cooperative Oncology Group; sb, sol-
vent-based.
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Discussion
Previous studies have suggested that sb-paclitaxel qw or doc-
etaxel q3w is more effective than sb-paclitaxel q3w for the
treatment of breast cancer.(9,10) Although nab-paclitaxel qw is
already considered as standard therapy in patients with MBC
in comparison with sb-paclitaxel q3w, it should also be evalu-
ated in comparison with sb-paclitaxel qw or docetaxel q3w.
Given that nab-paclitaxel qw demonstrated dose dependent
efficacy in a previous phase II study by Gradishar et al.,(19)
which showed longer PFS with nab-paclitaxel qw than doc-
etaxel q3w in Western countries, we investigated the efficacy
of 150 mg/m2 nab-paclitaxel qw. In contrast to the previous
study, nab-paclitaxel did not significantly prolong median PFS
compared with docetaxel in Japanese patients, and failed to
meet the primary endpoint of the study. In calculating our
sample size, we estimated the median PFS (11.8 months for
nab-paclitaxel and 7.5 months for docetaxel) based on the
results of the previous phase II study (19); however, PFS in the
nab-paclitaxel and docetaxel arms were actually 9.8 and
11.2 months, respectively. The patient characteristics in our
study differed from those in the previous study; approximately
30% of patients in our study received adjuvant taxane therapy,
while patients with prior adjuvant taxane therapy were not
enrolled in the previous phase II study. Variation within our
study population in terms of prior chemotherapy with taxanes
(13.3% sb-paclitaxel and 14.3% docetaxel in nab-paclitaxel
arm, and 20.2% sb-paclitaxel and 10.1% docetaxel in doc-
etaxel arm) may also have contributed to the discrepancy
between our results and those of the previous study. On the
other hand, our stratified analysis demonstrated that the median
PFS was longer in patients without prior adjuvant taxane ther-
apy compared with overall patients, similar to the previous
phase II study.(19)
The median PFS in the docetaxel arm was longer than origi-
nally estimated, which might have been partly because of dif-
ferent dose levels between the two studies. Although the
docetaxel dosage in the previous phase II study (100 mg/m2)
was higher than in the present study (75 mg/m2), the median
PFS in our docetaxel arm was longer than in reported in the
previous study. The results of both the present and previous
studies suggest that, although the anti-tumor efficacy and toxi-
city of docetaxel are reported to be dose-dependent in the
range of 60–100 mg/m2, 75 mg/m2 appears to be a better start-
ing dosage in terms of maintaining the relative dose intensity
by managing adverse events, demonstrating efficacy in Japa-
nese patients.(24–26) In the present study, patients treated with
nab-paclitaxel had a longer median TTF (7.0 months vs
5.7 months) and median OS (42.4 months vs 34.0 months)
Table 2. Stratified PFS assessed by independent radiologist and investigator
Treatment Patients
PFS, months Hazard ratio†
P-value
Group n Median 90% CI HR 90% CI
Evaluated by independent radiologist
Prior taxane therapy No Nab-paclitaxel 71 10.9 8.5, 12.5 1.05 0.72, 1.53 0.824
Docetaxel 71 9.9 7.8, 12.6
Yes Nab-paclitaxel 27 8.4 6.9, 12.6 1.73 0.94, 3.17 0.133
Docetaxel 28 15.3 11.2, 18.1
Evaluated by investigator
Prior taxane therapy No Nab-paclitaxel 71 11.3 9.4, 14.2 0.73 0.51, 1.06 0.166
Docetaxel 71 9.8 7.8, 11.1
Yes Nab-paclitaxel 27 9.8 8.4, 16.5 0.99 0.56, 1.75 0.983
Docetaxel 28 12.5 9.3, 15.4
Analysis set: full analysis set. †Cox’s proportional hazards model was used. CI, confidence interval; HR, hazard ratio; n, number of patients; PFS,
progression-free survival.
Table 3. Best overall response











n (%) n (%) n (%) n (%)
CR 1 (1.0) 1 (1.0) 0 (0.0) 0 (0.0)
PR 54 (55.1) 51 (51.5) 60 (61.2) 54 (54.5)
SD 36 (36.7) 34 (34.3) 35 (35.7) 34 (34.3)
PD 5 (5.1) 7 (7.1) 1 (1.0) 6 (6.1)
NE 2 (2.0) 6 (6.1) 2 (2.0) 5 (5.1)
Overall response rate (CR + PR) 55 (56.1) 52 (52.5) 0.669 60 (61.2) 54 (54.5) 0.388
95% CI (%) (45.7, 66.1) (42.2, 62.7) (50.8, 70.9) (44.2, 64.6)
Disease-control rate (CR + PR + SD) 91 (92.9) 86 (86.9) 0.238 95 (96.9) 88 (88.9) 0.049
95% CI (%) (85.8, 97.1) (78.6, 92.8) (91.3, 99.4) (81.0, 94.3)
Analysis set: full analysis set. †Fisher’s exact test. CI, confidence interval; CR, complete response; NE, not evaluable; PD, progressive disease; PR,
partial response; SD, stable disease.
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compared with docetaxel, though the differences were not sig-
nificant. Importantly, there was a discrepancy between the PD
rates in the nab-paclitaxel arm determined by investigators and
those determined by independent radiologist assessment, possi-
bly because investigators analyzed the images taking account
of the clinical symptoms of each patient. Assessment of OS is
considered to be more objective than PFS. The difference in
relative dose intensities between the two treatment arms should
also be noted; the median relative dose intensity in the nab-
paclitaxel arm was 70.2%, which was lower than that in the
docetaxel arm (83.5%), and was also lower than that in the
previous phase II study.(27) In our study, the dose reduction
rate in the nab-paclitaxel arm was higher than in the docetaxel
arm. The relative dose intensity of the standard 80 mg/m2
paclitaxel is reported more than 90% (28). Lower dose intensity
might be one of the reasons for PFS not prolonged compared
with docetaxel in this study, although treatment with nab-
paclitaxel 150 mg/m2 qw for multiple cycles was tolerable
with dose interruptions or dose reductions, as reported in a
phase I study in Japanese patients with MBC.(20)
Subgroup analysis of patients with TNBC in our study
showed no significant difference in either PFS or ORR
between the two treatment arms, though OS was longer in the
nab-paclitaxel arm compared with the docetaxel arm. The
GeparSepto study(29) showed that nab-paclitaxel increased the
pathological CR rate compared with sb-paclitaxel, as part of
sequential taxane–epirubicin/cyclophosphamide neoadjuvant
treatment in patients with early breast cancer, implying
remarkable efficacy in patients with TNBC. Furthermore, com-
binations of new immunotherapeutic agents and nab-paclitaxel
have recently been tested in patients with TNBC.(30–32) More
immunotherapeutic agents are expected to become available,
and nab-paclitaxel may thus play a role as a basis for the
development of new therapies.
The safety and tolerability profiles of nab-paclitaxel in the
present study were similar to those in Gradishar et al.’s phase
II study.(19) Docetaxel resulted in a much higher incidence of
grade 4 neutropenia than nab-paclitaxel, and more patients in
the docetaxel arm required G-CSF treatment. Febrile neutrope-
nia also occurred more often in the docetaxel arm. Given that
febrile neutropenia is risk factor for infection-related morbidity
and mortality, and that frequent G-CSF use may decrease
patient quality of life during treatment, nab-paclitaxel qw may
be preferable, especially for elderly or less fit patients.
Although the incidence of grade 3 peripheral sensory neuropa-
thy was higher in the nab-paclitaxel arm, this was comparable
to previous studies in other countries.(19)
Macular edema has been reported in patients treated with
taxanes. In this study, macular edema occurred in nine patients
(9.0%), and only in the nab-paclitaxel arm. Careful monitoring
of subjective symptoms, such as decreased visual acuity, and
appropriate adjustment of the study drug, including dose reduc-
tion or interruption, are needed to prevent the symptoms from
worsening towards irreversible macular damage.
This was the first randomized study to evaluate the weekly
administration of 150 mg/m2 nab-paclitaxel in Japanese
patients with MBC. Our results suggest that nab-paclitaxel qw
shows similar efficacy to docetaxel q3w in Japanese patients.
Safety was as expected for nab-paclitaxel and docetaxel; no
new profiles were observed, and the frequency of febrile
Table 4. Adverse events occurring in ≥30% of patients in any treatment group
Nab-paclitaxel (n = 100) Docetaxel (n = 100)
Any grade ≥Grade 3 Any grade ≥Grade 3
n (%) n (%) n (%) n (%)
Any adverse events 100 (100.0) 88 (88.0) 100 (100.0) 99 (99.0)
Hematologic toxicity
Neutropenia 97 (97.0) 78 (78.0) 99 (99.0) 98 (98.0)
Leukopenia 96 (96.0) 58 (58.0) 99 (99.0) 90 (90.0)
Non-hematotologic toxicity
Alopecia 95 (95.0) 0 91 (91.0) 0
Peripheral sensory
neuropthy
88 (88.0) 22 (22.0) 69 (69.0) 5 (5.0)
Rash 61 (61.0) 1 (1.0) 50 (50.0) 0
Nail disorder 57 (57.0) 0 57 (57.0) 0
Anemia 51 (51.0) 5 (5.0) 36 (36.0) 1 (1.0)
Arthralgia 47 (47.0) 1 (1.0) 40 (40.0) 0
Diarrhea 44 (44.0) 0 48 (48.0) 2 (2.0)
Muscle pain 44 (44.0) 1 (1.0) 46 (46.0) 0
Nausea 43 (43.0) 1 (1.0) 44 (44.0) 0
Stomatitis 42 (42.0) 1 (1.0) 34 (34.0) 0
Taste disturbance 42 (42.0) 0 67 (67.0) 1 (1.0)
Edema 40 (40.0) 3 (3.0) 51 (51.0) 4 (4.0)
Malaise 40 (40.0) 1 (1.0) 44 (44.0) 1 (1.0)
Loss of appetite 39 (39.0) 3 (3.0) 49 (49.0) 0
Nasopharyngitis 38 (38.0) 0 36 (36.0) 0
Fatigue 33 (33.0) 1 (1.0) 31 (31.0) 0
Constipation 25 (25.0) 1 (1.0) 30 (30.0) 0
Fever 20 (20.0) 0 30 (30.0) 0
Analysis set: all treated patients.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
Cancer Sci | May 2017 | vol. 108 | no. 5 | 992
Original Article
Randomized phase II study of nab-paclitaxel www.wileyonlinelibrary.com/journal/cas
neutropenia was higher in the docetaxel arm. A better under-
standing of the safety and efficacy profiles of each drug will
allow personalized treatments to be proposed based on the
individual patient’s characteristics.
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